Latest News
Kyverna Therapeutics, Inc.
- Kyverna Therapeutics Investor Advances Drug Data IPO Suit (1)
- Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
- Kyverna’s stiff-person syndrome trial shows one-year durability
- Kyverna Reports One-Year miv-cel Data in Stiff Person Syndrome, gMG
- Form 8K Kyverna Therapeutics Inc For: 24 September By Investing.com
- Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
- Kyverna Therapeutics reports positive one-year miv-cel data in SPS; rolling BLA on track for Q4
- Kyverna reports durable 1-year miv-cel datain autoimmune disease CAR-T race
- Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T
- Kyverna builds case for CAR-T in stiff person syndrome
- Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials - Slideshow (NASDAQ:KYTX) 2026-09-24
- Kyverna’s cell therapy shows lasting autoimmune benefit
Headlines from the last 30 days, linking to the original publishers. See all market news →